[Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].
Selective cyclooxygenase-2-inhibitors (COX-2) were developed as an alternative to the non-steroidal anti-inflammatory drugs (NSAID) in order to reduce their known gastrointestinal and renal toxicity. Several recent studies have shown the complex mechanism of the cyclooxygenase-2. The inhibition of the COX-2 has effects on renal hemodynamics, renal salt and water retention and may increase the thromboembolic and therefore the cardiovascular risk. The renal toxicity of the COX-2 inhibitors is similar to that of traditional NSAID. Regarding these data, COX-2 inhibitors should be prescribed with much caution to high risk patients, that is, patients with renal failure and/or cardiovascular diseases.
Mathieu
C
C
Abteilung für Nephrologie, Centre Hospitalier Universitaire Vaudois, Lausanne.
Meier
P
P
Meyer zu Starten
A
A
Burnier
M
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000633:toxicity*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000401:mortality; D009288:Naproxen / Q000008:administration & dosage / Q000633:toxicity; D011720:Pyrazoles / Q000008:administration & dosage / Q000633:toxicity; D018570:Risk Assessment; D013449:Sulfonamides / Q000008:administration & dosage / Q000633:toxicity; D013923:Thromboembolism / Q000139:chemically induced / Q000401:mortality
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D009288:Naproxen; D000068579:Celecoxib